A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice
| Autor: | Meyer, Kathleen E. a, Lorget, Florence b, Prawdzik, Gregg c, Falaleeva, Marina a, Cao, Liching a, Falese, Lillian d, Huston, Marshall W. e, Hettini, Khaled a, Lu, Yanmei a, Ledeboer, Annemarie a |
|---|---|
| Zdroj: | In Molecular Genetics and Metabolism February 2024 141(2) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect